Work Here?
About Unlearn AI
Industries
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$130.7M
Headquarters
San Francisco, California
Founded
2017
Overview
Unlearn.AI creates digital twins of patients using artificial intelligence, which are virtual replicas that simulate potential health outcomes. This technology allows healthcare providers to predict how a patient's health may change over time, leading to more informed treatment decisions. The primary clients include healthcare providers and pharmaceutical companies, who can use these digital twins in clinical trials to replace traditional control groups, potentially speeding up drug development and approval processes. Unlearn.AI operates in the digital health market, offering its AI-powered simulation technology through a service or subscription model. The goal is to enhance decision-making in patient care and drug development by providing precise health outcome predictions.
Simplify's Take
What believers are saying
- AI adoption in clinical trials is projected to grow significantly by 2034.
- Digital twins in healthcare market expected to reach $59.94 billion by 2030.
- Unlearn's collaboration with ProJenX showcases real-world application of its technology.
What critics are saying
- Rapid market growth may attract competition, threatening Unlearn AI's market share.
- High clinical trial failure rates could impact Unlearn AI's partnerships.
- Crowded AI-based clinical trial market requires continuous innovation from Unlearn AI.
What makes Unlearn AI unique
- Unlearn AI's TwinRCT uses digital twins to enhance clinical trial precision.
- The company integrates machine learning with biostatistics for improved trial outcomes.
- Unlearn AI's digital twin technology reduces the need for human control groups.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$130.7M
Above
Industry Average
Funded Over
5 Rounds
Insight PartnersIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Commuter Benefits
Paid Parental Leave
Company Equity
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 3%2 year growth
↑ 9%DELRAY BEACH, Fla., May 5, 2025 /PRNewswire/ -- The global Digital Twins in Healthcare Market, valued at US$2.69 billion in 2024, is forecasted to grow at a robust CAGR of 68.0%, reaching US$4.47 billion in 2025 and an impressive US$59.94 billion by 2030. Several factors are expected to drive market growth in the coming years, including increased investments from public and private entities, the expanding applications of digital twins, and technological advancements. AI and machine learning algorithms can help analyse and interpret large volumes of data, identify trends, and forecast outcomes, particularly as data from sources like healthcare providers and payers become more accessible. Additionally, collecting real-time patient data through the Internet of Things (IoT) can enhance remote monitoring and accelerate decision-making.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74014375Browse in-depth TOC on "Digital Twins in Healthcare Market"226 - Tables55 - Figures254 - PagesBy Based on type, the digital twins in healthcare market is segmented into process twins, system twins, whole body twins, and body part twins. The process twins segment accounted for the largest share of the market in 2024. The key factors contributing to the growth of this market include advancements in technology, improved data availability, and the increasing demand for personalized, efficient, and predictive healthcare delivery
Unlearn appoints Krates Ng as Chief Technology Officer to lead next phase of technological and operational expansion.
Ng joins Unlearn after serving as the Chief Technology Officer at ProducePay since December 2021.
DELRAY BEACH, Fla., Dec. 17, 2024 /PRNewswire/ -- The global artificial intelligence in clinical trials market is forecasted to grow steadily from US$1.20 billion in 2023 to US$1.35 billion in 2024, ultimately reaching an impressive US$2.74 billion by 2030, driven by a robust CAGR of 12.4%. Some of the key elements fueling the expansion of the AI in clinical trials market, are the high rate of clinical trial failures, the increasing need of anticipating drug pharmacokinetics, pharmacodynamics, and management of toxicity. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The reasons that may result in failure include but not limited to effectiveness in a clinical setting, high levels of toxicity that cannot be managed, suboptimal drug-like characteristics, a lack of real commercial drivers, and poor strategic design
Clinical-stage biotechnology company ProJenX has announced a collaboration with Unlearn to implement generative AI technology for a Phase I PRO-101 trial of prosetin, a potential amyotrophic lateral sclerosis (ALS) treatment.
Unlearn AI is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Unlearn AI
Industries
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$130.7M
Headquarters
San Francisco, California
Founded
2017
Unlearn AI is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today